Methods of Treating Malignant Lymphoproliferative Disorders
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 2 of these applications claim priority to application PCT/US2019/035576, filed Jun 5, 2019. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Patent lifetimeUsedRemaining | Confidence |
|---|---|---|---|---|---|---|
| US 11,510,904 | Methods of Treating Malignant Lymphoproliferative Disorders In force · High confidence UsedRemaining | Actuate Therapeutics Inc. | In force | High confidence | ||
| US 11,980,607 | Methods of Treating Malignant Lymphoproliferative Disorders In force · High confidence | Actuate Therapeutics Inc. | In force | High confidence | ||
| Application 18/630,283 | Methods of Treating Malignant Lymphoproliferative Disorders Abandoned Abandoned Nov 14, 2025 | Actuate Therapeutics Inc. | Abandoned | Abandoned Nov 14, 2025 |
3 of 3 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
2 of these are in force and held by Actuate Corporation.
Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.